H
yperphosphatemia has been associated with decreased survival rate and severe morbidity in dogs 1, 2 and cats 3, 4 with CKD. Plasma phosphorus concentration has been documented as a predictor for progression of CKD in cats, with a 41% increase in the risk of disease progression for every increase of 1 mg/dL. 5 Clinical signs of secondary renal hyperparathyroidism, such as bone demineralization, soft tissue calcification, renal osteodystrophy, and metastatic calcifications, have been reported for both dogs and cats. [6] [7] [8] [9] In particular, metastatic calcifications in the paws have been suggested to develop when sCaPP is > 70 mg 2 /dL 2 . 10 In humans, sCaPP can be accurately determined from measurements of serum phosphorus concentration and either total or ionized calcium concentration and provides a clinically relevant means of estimating cardiovascular risk associated with CKD. 4 Bone disorders and mineral disorders represent interrelated serum biochemical, bone, and vasculature abnormalities often associated with CKD.
High sCaPP is associated with a major risk of ectopic calcifications that can contribute to soft tissue calcium phosphate deposits. Humans with end-stage renal disease and a high sCaPP have significantly more calcified coronary plaques than do controls. [11] [12] [13] High sCaPP may result in increased calcium deposition in coronary artery plaques and promote plaque rupture. In humans, myocardial calcification has been reported to be positively correlated with high sCaPP and inversely correlated with left ventricular function. 14 In particular, deaths resulting from coronary artery disease and sudden deaths were significantly related to high sCaPP as a linear function.
14 For every increase in sCaPP of 10 mg 2 /dL 2 , the relative risk of sudden death increases by 7%.
14 In dogs with naturally occurring CKD, sCaPP appears to increase with progression of the disease. In 1 study 15 of dogs with CKD, sCaPP was found to be correlated to serum parathyroid hormone concentration, and in dogs with CKD at IRIS stage 3 (serum creatinine concentration, 2.1 to 5 mg/dL) or worse, sCaPP was significantly different from that in healthy control dogs. No data regarding high sCaPP and risk of death in dogs affected by CKD are available, to our knowledge.
The purpose of the study reported here was to retrospectively assess the usefulness of sCaPP as a predic-tor of mortality rate in a group of dogs with naturally occurring CKD at different stages of severity. An sCaPP > 70 mg 2 
/dL
2 was hypothesized to be associated with increased mortality rate in dogs with CKD.
Materials and Methods
Case selection and medical records reviewRecords of client-owned dogs of different breeds, sex, age, and weight referred to the Mario Modenato Veterinary Teaching Hospital for nephrological consultation between December 2008 and December 2010 were reviewed. Apparently healthy dogs had been referred to the nephrology service because of previous episodes of polyuria and polydipsia or evaluation of overall renal function before minor surgery. For each dog, data regarding history, results of biochemical analyses and urinalysis, and ultrasonographic findings were collected from the medical record to confirm the diagnosis of primary renal disease and its chronic nature or to determine that the dog was healthy. At the time of the initial examination, the dog' s history was recorded and a complete clinical evaluation was performed; findings of that evaluation were included in the medical record. All dog owners were asked for informed consent so that serum and plasma samples could be stored for research purposes.
Results of a renal panel together with those of a CBC (volume of blood used, 5 mL) and urinalysis performed at the time of the initial examination were obtained from the medical record of each dog; variables of interest included plasma concentrations of creatinine and urea and serum concentrations of albumin, total protein, total and ionized calcium, and phosphorus. Inclusion criteria for dogs with CKD included a documented history of CKD and ultrasonographic findings and laboratory test results indicating stable CKD of at least 3 months' duration. Exclusion criteria for dogs with CKD included a documented history of acute kidney injury, ultrasonographic findings or laboratory signs of acute kidney injury, and serum azotemia secondary to urinary obstruction or volume-responsive acute kidney injury. For dogs with CKD, the stage of disease was classified according to the 2011 IRIS guidelines 16 Glomerular filtration rate was tested in each dog by means of an iohexol plasma clearance assay, and results were obtained from the medical record. In the present study, plasma iohexol clearance < 60 mL/min/m 2 was considered to represent a decreased GFR. 17, 18 Additional data obtained for dogs with CKD included clinical signs at the initial evaluation and prescribed treatments and diets. For dogs with CKD, follow-up information was available for a 455-day period or until time of death; for healthy dogs, information was obtained from owners at 6-month intervals.
Plasma iohexol clearance assay-Prior to the assay procedure, food was withheld from each dog for 12 hours. Each dog was accurately weighed, and an IV catheter was placed in each cephalic vein. One of those catheters was used to collect the blood samples and the other to administer the contrast medium. Before injection of the contrast medium (iohexol a ), an initial blood sample (0.5 mL) was collected and put into a tube containing heparin. The syringe used for contrast medium administration was weighed before addition of the contrast medium (empty weight), when full of iohexol (preadministration weight), and after the injection of contrast medium into the dog (postadministration weight) to determine the exact injected dose. The contrast medium was slowly administered through the IV catheter (64.7 mg/kg [29.41 mg/lb] dose administered in a 60-second period). The completion of the injection represented the 0-minute time point. A blood sample (0.5 mL) was obtained from each dog on 5 occasions: at 5, 15, 60, 90, and 180 minutes. Blood samples were collected in tubes containing heparin and centrifuged to obtain plasma. Each plasma sample underwent high-performance liquid chromatography analysis. Plasma iohexol concentration-time curves were analyzed through a bicompartmental kinetic model. 17, 18 Biochemical analyses-Plasma creatinine and urea concentrations and serum total calcium, phosphorus, and albumin concentrations were measured by use of a laboratory analyzer.
b Serum ionized calcium concentration was determined through a selective ion hemogas analysis machine, c which measures potential difference of the sample. The sCaPP was calculated by multiplying serum total calcium concentration by serum phosphorus concentration. An sCaPP > 70 mg 2 /dL 2 was considered abnormal, and an sCaPP ≤ 70 mg 2 /dL 2 was considered normal.
Statistical analysis-Statistical analysis was performed with standard software programs.
d,e All data were tested for normality by means of the KolmogorovSmirnov test. The data are reported as median and range. A value of P < 0.05 was considered significant. Variance analysis among mean values of sCaPP in healthy dogs and in dogs with IRIS stage 1, 2, 3, or 4 disease was performed by means of a Kruskal-Wallis test followed by a Dunn multiple comparison test. Linear regression analysis and Spearman correlation coefficient analysis were used to assess the correlation of plasma creatinine concentration and sCaPP, plasma creatinine and serum phosphorus concentrations, and plasma creatinine and serum calcium concentrations for dogs at each stage of the IRIS classification. Kaplan-Meier survival curves were determined for dogs that had an sCaPP ≤ and > 70 mg 2 /dL 2 within the study population and for dogs at each IRIS disease stage. Cox proportional hazards regression models were used to examine the association of survival rate and initial serum ionized calcium concentration, serum phosphorus concentration, sCaPP, plasma creatinine concentration, feeding of a diet formulated for dogs with CKD (renal diet), and administration of phosphate binders.
Results
Of 102 dogs referred for nephrological consultation between December 2008 and December 2010, 66 were eligible for inclusion in the study. For 31 of these 66 dogs, a definitive diagnosis of CKD had been made on the basis of azotemia, reduced urine specific gravity, renal proteinuria (urinary protein-creatinine concentration ratio, > 0.5), and abnormal renal morphology detected during ultrasonographic examina-tion. 16 The stages of disease (according to IRIS guidelines 16 ) among these 31 dogs were as follows: stage 2, 7 dogs; stage 3, 13 dogs; and stage 4, 11 dogs. Owing to the retrospective nature of the study, it was not possible to enroll the same number of dogs for each stage of IRIS disease classification. As a consequence, there was a significantly lower number of dogs with stage 2 CKD, compared with the number of dogs at each of the other stages of disease and the number of healthy dogs.
In the remaining 35 dogs, no abnormalities were detected by CBC, biochemical analyses, urinalysis, or ultrasonography, although some dogs had had previous episodes of polyuria and polydipsia. However, for purposes of the present study, plasma iohexol clearance < 60 L/min/m 2 was considered to represent a decreased GFR. On the basis of GFR assessments, 13 of these 35 apparently healthy dogs were considered to have early CKD and were classified as having IRIS stage 1 disease (plasma creatinine concentration < Data regarding plasma creatinine concentration, sCaPP, and serum ionized calcium, total calcium, and phosphorus 
IRIS disease stage

Variable
Healthy dogs 1 (n = 13) 2 (n = 7) 3 (n = 13) 4 (n = 11) Spearman tests revealed no significant correlation between plasma creatinine concentration and sCaPP in healthy dogs and dogs with stage 1, 2, or 3 disease; between plasma creatinine and serum phosphorus concentrations in healthy dogs and dogs with stage 1, 2, or 3 disease; and between plasma creatinine and serum total calcium concentrations in healthy dogs and dogs with stage 1, 2, 3, or 4 disease. In dogs with stage 4 disease, significant correlations were found between plasma creatinine concentration and sCaPP (P = 0.03; R = 0.79) and between plasma creatinine and serum phosphorus concentrations (P = 0.02; R = 0.78; Figure 1 ).
All healthy dogs and dogs with stage 1 and 2 disease had sCaPP ≤ 70 mg /dL 2 could not be computed because > 50% of dogs were still alive at the end of the study (Figure 2) .
Results of Cox proportional hazards regression analysis indicated that survival time was not affected by initial serum ionized calcium concentration, serum phosphorus concentration, plasma creatinine concentration, feeding of a renal diet, or administration of phosphate binders. Only sCaPP was significantly (P = 0.04) associated with a reduction in the survival time (Table 2) . Furthermore, the Cox regression coefficient was positive for sCaPP, indicating that the increase in sCaPP was related to a higher probability of death.
Discussion
Results of the present retrospective study in dogs with CKD indicated that high sCaPP seemed to develop more in the late than early stages of the disease. Median sCaPP increased significantly with the progression of the stage of disease. No dogs in the early stages of the disease (IRIS stages 1 and 2) were receiving phosphate binders or other medications to alter calciumphosphorus metabolism, so the discrepancy in serum phosphorus concentration and sCaPP between dogs in the early and late stages of CKD may suggest an increased urinary excretion of phosphorus in dogs with stage 1 or 2 disease, compared with dogs with stage 3 or 4 disease. Regardless, although high sCaPP and hyperphosphatemia were more prevalent in dogs with latestage CKD, no significant correlation between sCaPP and plasma creatinine concentration or between serum phosphorus and plasma creatinine concentrations was found in dogs with stage 1, 2, or 3 disease. In dogs with stage 4 disease, both the sCaPP (P = 0.03; R = 0.79) and serum phosphorus concentration (P = 0.02; R = 0.78) had a positive linear correlation with plasma creatinine concentration. This finding may be related to the different effect of progressive modifications of GFR on urinary phosphorus excretion. Most dogs with stage 4 disease with high sCaPP had both hyperphosphatemia and hypocalcemia. In this group of dogs, the increase in serum phosphorus concentration was sufficiently high to balance out the reduction in serum ionized calcium concentration and to result in an sCaPP > 70 mg 2 In the present cohort of dogs with CKD, Cox proportional hazards regression analysis revealed that the role of increased sCaPP as a predictor of negative outcome was not influenced by concomitant administration of a renal diet or phosphate binders. Serum calciumphosphorus concentration product seemed to be a more reliable index of negative outcome than serum total calcium or phosphorus concentration. This finding may be explained by the fact that serum calcium and phosphorus concentrations can be modified independently. High serum phosphorus concentrations may be associated with normal to high serum total calcium concentrations, resulting in high sCaPP. Moreover, serum phosphorus concentration may be so high as to overlap a condition of hypocalcemia, leading to high sCaPP. On the other hand, if hypocalcemia is very severe or hyperphosphatemia is not markedly high, the sCaPP may be apparently normal. The sCaPP appears to be a better indicator of calcium-phosphorus modifications than either serum calcium or phosphorus concentration alone.
The present study-a retrospective investigation designed to assess the role of sCaPP as a predictor of mortality rate in a group of dogs at different stages of naturally occurring CKD-had several limitations. Owing to the retrospective nature of the study, it was not possible to enroll the same number of dogs for each stage of IRIS disease classification. As a consequence, there was a significantly lower number of dogs with stage 2 CKD, compared with the number of dogs at each of the other stages of disease and the number of healthy dogs.
Follow-up of the study dogs was limited to evaluation of mortality rate over a 455-day period but did not consider changes over time in sCaPP and serum concentrations of phosphorus, total calcium, and ionized calcium and plasma concentrations of creatinine and urea. Only sCaPP measured at the first evaluation at the nephrology service of the Mario Modenato Veterinary Teaching Hospital was assessed, and measurements obtained at subsequent recheck examinations were not analyzed. Also, given the retrospective nature of the present study, we did not evaluate concentrations of either parathyroid hormone or fibroblast growth factor-23, so it was not possible to diagnose early stages of secondary renal hyperparathyroidism among the dogs.
In the present study, a cutoff of sCaPP at 70 mg 2 / dL 2 was chosen to classify values as normal or abnormal because, in humans with CKD, an sCaPP > 70 mg 2 / dL 2 is related to an increase relative risk of death and negative outcome.
14 In cats and dogs, an sCaPP > 70 mg 2 /dL 2 is related to a higher prevalence of metastatic calcifications. 10 In human medicine, recommendations 
